With a balanced mix of upfront consideration, performance-based milestones, we expect significant financial synergies and we maintain a disciplined financial profile with a clear path to deleverage to below 3x by 2028. Let me turn it over to Chintu to share more about Kashiv.This unlocks direct access to more than $300 million of worldwide biologic loss of exclusivity over the next decade by bringing together Kashiv's deep R&D and manufacturing capabilities with our proven commercial scale. This combination ...

Amneal Pharmaceuticals (NASDAQ:AMRX) Delivers Strong Financial Results and Positive OutlookAmneal Pharmaceuticals reported robust first-quarter financial performance, with earnings per share (EPS) of $0.27 significantly exceeding analyst estimates and revenue reaching $722.52 million.The company raised its adjusted EPS guidance for 2026 to a range of $0.95 to $1.05, reflecting a positive future outlook for the pharmaceutical stock.Strategic initiatives, including the acquisition of Kashiv BioSciences to enh ...